Part ofPrescription Drugs →

AB 1887CALIFORNIASession 20252026

California requires health plans to approve rare disease drug requests within 30 days

Original title: Prescription drug coverage for rare diseases.

August 30, 2026

Prescription Drugs Rare Diseases Health Insurance Healthcare Regulation Prescriptiondrugcoverageforrarediseases

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Currently Unknown. The next step in the legislative lifecycle is Introduced.

Version history & redline

4 versions on file

Official version history is partial: 4 linked texts are unavailable or incomplete. Source links remain available below.

Comparing 03/26/26 - Amended Assembly → 05/20/26 - Amended Assembly

removed addedOfficial text

The text diff for this stage has not been computed yet.

pdf extract failed: Invalid PDF structure.

Redline computed from the official version text (record lane).View this version →

The Frame

What this does

This bill establishes a strict timeline for insurance coverage decisions, ensuring patients with rare diseases do not face indefinite delays for their only available treatment options.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Patients with rare diseases

Patients may receive faster coverage determinations for their only available FDA-approved treatment.

Health care service plans

Plans must adjust their prior authorization processes to meet the 30-day deadline for specific rare disease drugs.

Health insurers

Insurers must comply with the new 30-day prior authorization timeline for rare disease treatments.

What changed

Last recorded activity August 30, 2026.

What's next

Introduced.

Summary

Starting January 1, 2027, health insurance plans must complete requests within 30 days for FDA-approved drugs used to treat rare diseases. This requirement applies when a specialist determines the drug is medically necessary and it is the only FDA-approved treatment available for that condition.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This bill establishes a strict timeline for insurance coverage decisions, ensuring patients with rare diseases do not face indefinite delays for their only available treatment options.

Frequently Asked Questions

Does this apply to all prescription drugs?

No, it specifically applies to drugs approved by the FDA for the treatment of a rare disease where that drug is the only FDA-approved treatment available.

What happens if an insurance company fails to meet the 30-day deadline?

The bill notes that a willful violation of these provisions by a health care service plan would be a crime.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift100% confidence

Mandated Timeline for Rare Disease Coverage

The bill shifts from general prior authorization standards to a specific, time-bound mandate for rare disease treatments, effectively limiting the insurer's ability to delay coverage decisions for these specific cases.

Department of Managed Health Care Department of Insurance

Connected Entities

organizationDepartment of Managed Health Care“Regulator of health care service plans.”Map →

organizationUnited States Food and Drug Administration“Approves drugs for the treatment of rare diseases”Map →

otherKnox-Keene Health Care Service Plan Act of 1975“Existing law governing health care service plans.”Map →

organizationDepartment of Insurance“Regulator of health insurers.”Map →

Sources

Open source document

openstates.org

Analysis Score

0–100

Significance75
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz30
Current news / social attention level

Publisher tools